Pulse Biosciences (PLSE) news
Recent news
Pulse Biosciences announces inducement grants under Nasdaq listing rule 5635(c)(4)
AInvest Wire · Aug 18, 2026Pulse Biosciences Inc: Needham initiates coverage with buy rating; target price $58
Needham & Co. has initiated coverage of Pulse Biosciences (Nasdaq: PLSE) with a "Buy" rating and a $58 price target, citing the company’s nsPFA technology and early clinical progress in atrial fibrillation (AF) treatment. The analyst highlighted the potential for clinical data or partnership…
AInvest Wire · Aug 17, 2026Pulse Biosciences - targets CE Mark submission in H2 2026, potential approval by mid-2027
AInvest Wire · Aug 6, 2026Pulse Biosciences - establishes new $75 mln ATM facility, maintains $125 mln shelf registration
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced the establishment of a new $75 million at-the-market (ATM) equity offering facility, in addition to maintaining its existing $125 million shelf registration. The ATM program allows the company to issue and sell shares of its common stock from…
AInvest Wire · Aug 6, 2026Pulse Bio may redeem warrants at exercise price of $11/share
AInvest Wire · Jun 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.